Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    Loans
    HomeNewsPawan chaudhary

    Pawan Chaudhary

    Jump to

    • Venus inks outlicensing deal for Elores with SA co

      The company, which has inked a memorandum of understanding (MoU) with Austell Laboratories, expects to launch the drug in South Africa by mid-2015.

    • Venus Remedies among the best companies to work for

      Venus Remedies Limited, a research-based global pharmaceutical firm is the only company from North India to have made it to the list of Top 100 in the "India‘s Best Companies to Work for" study conducted by the Great Place to Work Institute, India in association with The Economic Times.

    • Venus Remedies signs deal with Goodwills Co

      Pharma firm Venus Remedies today said it has signed a deal with South Korean drug company Goodwills Co Ltd for exclusive marketing of its antibiotic drug 'Elores'.

    • Venus Remedies bags Australian GMP from TGA

      Venus Remedies Limited, a research based global pharmaceutical company has reached another milestone in the form of Good Manufacturing Practices (GMP) approval from Therapeutic Goods Administration (TGA) Australia for four of its facilities - Cephalosporin, Carapenems, and Oncology liquid and Oncology lyophilized.

    • Venus eyes $100m from new drug 'Elores' in 5 years

      Venus Remedies today said it is aiming to garner around USD 100 million (over Rs 500 crore) in the next five years from its new drug that is used for combating spread of bacterial resistance.

    • Venus Remedies spreads its wings in GCC

      Panchkula based Venus Remedies Limited, an existing Eu-GMP certified Pharmaceutical manufacturing company, has once again achieved a very significant landmark in its list of achievements. It has now been awarded the company registration from GCC (Gulf Cooperation Council).

    • Venus Remedies drug 'GEMCITABINE' gets UK MHRA approval

      Venus Remedies Limited, a leading research based Indian pharmaceutical company achieved yet another landmark by receiving the Market Authorisation for GEMCITABINE, one of the key products for the treatment of Cancer via de-centralised procedure from Medicine and Healthcare Regulatory Agency (MHRA) U.K.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347